TGTX (Biotech) Stock Valuation & Fair Value
Mixed on our testsTGTX (Biotech) trades at a current P/E of 50.9, about 62% below its historical normal valuation, with a forward growth estimate of 67.2% and a PEG of 0.76. Priced at its historical normal P/E of 133.7 on the same blended earnings, the 2026-11-06 close of $59.83 corresponds to about $157 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Long-term debt is over half its capital (56%)
- Misses analyst estimates often (64%)
Frequently asked questions
Is TGTX overvalued?
At a current P/E of 50.9 versus its historical normal P/E of 133.7, TGTX trades about 62% below its typical valuation, with a PEG of 0.76 on 67.2% forward growth. tickerseer currently rates it mixed on our tests.
What is TGTX's fair value and PEG?
TGTX trades at a current P/E of 50.9 against a historical normal P/E of 133.7, a PEG of 0.76, and a forward growth estimate of 67.2%. Priced at its historical normal P/E of 133.7 on the same blended earnings, the 2026-11-06 close of $59.83 corresponds to about $157 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of TGTX changed?
tickerseer's rating has been mixed on our tests since 2026-11-07.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.